Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines - PubMed

Review

Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines

R A Asherson et al. Lupus. 2003.

Abstract

The term 'catastrophic' antiphospholipid syndrome (APS) is used to define an accelerated form of APS resulting in multiorgan failure. Although catastrophic APS patients represent less than 1% of all patients with APS, they are usually in a life-threatening medical situation that requires high clinical awareness. The careful and open discussion of several proposals by all participants in the presymposium workshop on APS consensus, held in Taormina on occasion of the 10th International Congress on aPL and chaired by Munther A Khamashta and Yehuda Shoenfeld (29 September 2002), has allowed the acceptation of a preliminary set of classification criteria. On the other hand, the optimal management of catastrophic APS must have three clear aims: to treat any precipitating factors (prompt use of antibiotics if infection is suspected, amputation for any necrotic organ, high awareness in patients with APS who undergo an operation or an invasive procedure), to prevent and to treat the ongoing thrombotic events and to suppress the excessive cytokine 'storm'. Anticoagulation (usually intravenous heparin followed by oral anticoagulants), corticosteroids, plasma exchange, intravenous gammaglobulins and, if associated with lupus flare, cyclophosphamide, are the most commonly used treatments for catastrophic APS patients.

Similar articles

• Catastrophic antiphospholipid syndrome.

  Cervera R, Asherson RA, Font J. Cervera R, et al. Rheum Dis Clin North Am. 2006 Aug;32(3):575-90. doi: 10.1016/j.rdc.2006.05.002. Rheum Dis Clin North Am. 2006. PMID: 16880085 Review.

• [Catastrophic antiphospholipid syndrome].

  Costedoat-Chalumeau N, Arnaud L, Saadoun D, Chastre J, Leroux G, Cacoub P, Amoura Z, Piette JC. Costedoat-Chalumeau N, et al. Rev Med Interne. 2012 Apr;33(4):194-9. doi: 10.1016/j.revmed.2012.01.005. Epub 2012 Feb 16. Rev Med Interne. 2012. PMID: 22341856 French.

• Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.

  Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y. Cervera R, et al. Lupus. 2011 Feb;20(2):165-73. doi: 10.1177/0961203310395051. Lupus. 2011. PMID: 21303833

• Anesthetic implications of the catastrophic antiphospholipid syndrome.

  Batra YK, Rajeev S. Batra YK, et al. Paediatr Anaesth. 2006 Oct;16(10):1090-3. doi: 10.1111/j.1460-9592.2006.01944.x. Paediatr Anaesth. 2006. PMID: 16972844

• Catastrophic antiphospholipid syndrome: report of 4 cases.

  Sinico RA, Di Toma L, Sabadini E, Renoldi P, Li Vecchi M. Sinico RA, et al. J Nephrol. 2007 Nov-Dec;20(6):739-44. J Nephrol. 2007. PMID: 18046677 Review.

Cited by

• The role of plasmapheresis in critical illness.

  Nguyen TC, Kiss JE, Goldman JR, Carcillo JA. Nguyen TC, et al. Crit Care Clin. 2012 Jul;28(3):453-68, vii. doi: 10.1016/j.ccc.2012.04.009. Crit Care Clin. 2012. PMID: 22713617 Free PMC article. Review.

• Recurrent thrombotic events after catastrophic antiphopholipid syndrome.

  Park HC, Yoon HB, Lee TW, Jung JY, Chin HJ, Kim YS, Kim S. Park HC, et al. Korean J Intern Med. 2012 Jun;27(2):232-4. doi: 10.3904/kjim.2012.27.2.232. Epub 2012 May 31. Korean J Intern Med. 2012. PMID: 22707899 Free PMC article. No abstract available.

• The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome.

  Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Puerta JG, Espinosa G, Bucciarelli S; Members of the CAPS Registry Group. Miesbach W, et al. Clin Rheumatol. 2007 Dec;26(12):2109-2114. doi: 10.1007/s10067-007-0634-x. Epub 2007 May 24. Clin Rheumatol. 2007. PMID: 17522949

• Predictors and clinical complications associated with antiphospholipid antibodies in sickle cell disease.

  Rivera CR, Srisuwananukorn A, Bajwa RJ, Gordeuk VR, Rauch J, Levine JS, Saraf SL. Rivera CR, et al. EJHaem. 2023 Jan 13;4(1):211-215. doi: 10.1002/jha2.643. eCollection 2023 Feb. EJHaem. 2023. PMID: 36819151 Free PMC article.

• Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.

  Ammirati E, Bizzi E, Veronese G, Groh M, Van de Heyning CM, Lehtonen J, Pineton de Chambrun M, Cereda A, Picchi C, Trotta L, Moslehi JJ, Brucato A. Ammirati E, et al. Front Med (Lausanne). 2022 Mar 7;9:838564. doi: 10.3389/fmed.2022.838564. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35350578 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal